Explosive internal emails from the Australian Therapeutic Goods Administration (TGA) reveal that the agency misled the public about risks associated with mRNA vaccines. Emails obtained via Freedom of Information requests show TGA officials were aware of potential DNA contamination from mRNA vaccines but chose to downplay these risks to maintain public trust in vaccinations. Dr. Mel McCann, who uncovered these emails, expressed shock that the TGA prioritized public reassurance over investigating these serious risks. This follows legal arguments from TGA lawyers that they owe no duty of care to citizens injured by vaccines they approved.
Key findings indicate that TGA staff were unaware of any testing regarding the integration of mRNA into the human genome. There were concerns related to a component in the Pfizer vaccine that can drag DNA into cells’ nuclei. The TGA's public communications reassured the public that such integration was impossible, yet internal emails acknowledged the biological possibility. The TGA previously issued a statement addressing misinformation about DNA levels in vaccines after a critical report alleged excessive levels in Australian vials.
Emails detail that TGA senior officials were aware of the presence of SV40 sequences in the Pfizer vaccine, which can promote DNA uptake into the nucleus, yet this information was not disclosed to the TGA by Pfizer. Discussions among TGA staff revealed an understanding that while integration of foreign DNA is unlikely, it is indeed possible through alternative mechanisms. Although the TGA insisted that DNA from mRNA vaccines cannot integrate into human DNA, their exchanges showed an acknowledgment of the risks associated with residual DNA.
Furthermore, the SV40 enhancer in the Pfizer modRNA vaccine was recognized internally as posing risk for genomic integration, contradicting the public stance that it was a not a safety concern. Missing from the internal risk discussions was the recognition that lipids encapsulating the vaccine could also carry residual DNA into cells efficiently, thus elevating the risk of contamination.
Concerns regarding the size and nature of residual DNA were discussed, focusing on its potential to lead to cancer or genomic changes. While agency staff asserted that the risks were low, they also highlighted a need for further investigation, indicating tensions with the public communications that dismissed any risk entirely.
Staff also questioned the reliability of the current understanding regarding residual DNA, noting that studies linking risks to naked DNA do not adequately consider the implications of packaged DNA in lipid nanoparticles. This area of uncertainty further complicates safety assessments regarding the vaccine. The internal discussions ultimately indicate significant gaps in the knowledge and communication around the risks posed by DNA contamination in mRNA vaccines, raising alarms about the accountability of the TGA to public health.
In summary, the TGA's internal communications reveal serious concerns about the safety of mRNA vaccines through potential DNA integration risks. While public statements downplayed these concerns, the agency's own staff acknowledged the biological plausibility of such events, highlighting the need for more thorough investigation and public transparency regarding vaccine safety.
Several scientists, including McKernan and Speicher, emphasize that the risks the TGA claims to mitigate have not been adequately addressed or validated, raising questions over regulatory standards and the accuracy of safety claims made to the public.
No comments:
Post a Comment